Cyclosporin A-insensitive permeability transition in brain mitochondria - Inhibition by 2-aminoethoxydiphenyl borate by Chinopoulos, Christos et al.
Cyclosporin A-insensitive Permeability Transition in
Brain Mitochondria
INHIBITION BY 2-AMINOETHOXYDIPHENYL BORATE*
Received for publication, April 11, 2003, and in revised form, May 12, 2003
Published, JBC Papers in Press, May 15, 2003, DOI 10.1074/jbc.M303808200
Christos Chinopoulos‡, Anatoly A. Starkov§, and Gary Fiskum‡¶
From the ‡University of Maryland School of Medicine, Department of Anesthesiology, Baltimore, Maryland 21201 and
§Weill Medical College, Cornell University, Department of Neurology, New York, New York 10021
The mitochondrial permeability transition pore (PTP)
may operate as a physiological Ca2 release mechanism
and also contribute to mitochondrial deenergization
and release of proapoptotic proteins after pathological
stress, e.g. ischemia/reperfusion. Brainmitochondria ex-
hibit unique PTP characteristics, including relative re-
sistance to inhibition by cyclosporin A. In this study, we
report that 2-aminoethoxydiphenyl borate blocks Ca2-
induced Ca2 release in isolated, non-synaptosomal rat
brainmitochondria in the presence of physiological con-
centrations of ATP and Mg2. Ca2 release was not me-
diated by the mitochondrial Na/Ca2 exchanger or by
reversal of the uniporter responsible for energy-depend-
ent Ca2 uptake. Loss of mitochondrial Ca2was accom-
panied by release of cytochrome c and pyridine nucleo-
tides, indicating an increase in permeability of both the
inner and outer mitochondrial membranes. Under these
conditions, Ca2-induced opening of the PTP was not
blocked by cyclosporin A, antioxidants, or inhibitors of
phospholipase A2 or nitric-oxide synthase but was abol-
ished by pretreatment with bongkrekic acid. These find-
ings indicate that in the presence of adenine nucleotides
andMg2, Ca2-induced PTP in non-synaptosomal brain
mitochondria exhibits a unique pattern of sensitivity to
inhibitors and is particularly responsive to 2-amino-
ethoxydiphenyl borate.
Mitochondria are temporo-spatial modulators of cytosolic
[Ca2] through their ability to both sequester and release Ca2
in concert with Ca2 transport across the endoplasmic reticu-
lum (1, 2). Physiological mitochondrial Ca2 efflux, including
that caused by Ca2-induced Ca2 release (mCICR),1 is attrib-
uted to either activation of the permeability transition pore
(PTP) (3, 4) or to reversal of the Ca2 uniporter (5). Opening of
the PTP has been implicated as a mediator of apoptotic and
necrotic cell death as well as a regulator of normal cell Ca2
homeostasis (4, 6–12). The characteristic traits of the PTP
include reversibility (13), sensitivity to inhibition by cyclo-
sporin A (14), and mitochondrial swelling associated with loss
of matrix solutes (15–17). Cyclosporin A is not always effective,
however, at inhibiting Ca2-induced mitochondrial swelling
and loss of  (18–22). In addition, the observation that nor-
mal intracellular concentrations of adenine nucleotides and
Mg2 partially or completely block PTP activation (23, 24) casts
doubt on a physiological role of the PTP.
The extent to which mitochondria swell in response to accu-
mulation of large Ca2 loads also varies considerably with
experimental conditions and with mitochondrial tissue type
(25–27). Brain mitochondria are particularly resistant to Ca2-
induced swelling (25, 28); moreover, they represent many cell
populations, which may explain their heterogeneous response
to large Ca2 loads and to inhibitors of the PTP, e.g. cyclosporin
A (26, 29).
In this study we report that 2-APB (30) prevents Ca2-
induced PTP in non-synaptosomal brain mitochondria in the
presence of physiological concentrations of ATP and Mg2.
2-APB is reported to inhibit Ca2 efflux from mitochondria in
situ in Jurkat T cells following stimulation of cellular Ca2
influx through activation of capacitative Ca2 entry (31). Un-
der these conditions, mitochondria transiently accumulate
Ca2, followed by release upon restoration of basal cytosolic
Ca2 levels. The investigators hypothesized that the inhibition
of mitochondrial Ca2 efflux by 2-APB is because of inhibition
of the mitochondrial Na/Ca2 exchanger (32). Our results do
not provide evidence for 2-APB inhibition of the mitochondrial
Na/Ca2 exchanger but do indicate that mCICR via the PTP
is effectively inhibited. This effect of 2-APB on isolated non-
synaptosomal brain mitochondria is observed both in the ab-
sence of adenine nucleotides, where inhibition of Ca2-induced
swelling is apparent, and in the presence of millimolar concen-
trations of ATP andmagnesium, where swelling is not observed
but where Ca2 induces release of matrix metabolites and
cytochrome c. In the presence of ATP, 2-APB-inhibitable Ca2-
induced mitochondrial alterations are not affected by most
other PTP inhibitors, including cyclosporin A.
EXPERIMENTAL PROCEDURES
Isolation of Mitochondria—Non-synaptic adult rat brain mitochon-
dria were isolated on a Percoll gradient as described previously (33)
with minor modifications. Male 300–350-g Sprague-Dawley rats were
used for this study. All animal procedures were carried out according to
the National Institutes of Health and the University of Maryland,
Baltimore, animal care and use committee guidelines. Rats were sacri-
ficed, and forebrains were rapidly removed, chopped, and homogenized
in ice-cold isolation buffer containing 225 mM mannitol, 75 mM sucrose,
5 mM Hepes, and 1 mM EGTA with the pH adjusted to 7.4 using KOH.
The brain homogenate was centrifuged at 1,250 g for 3 min; the pellet
was discarded, and the supernatant was centrifuged at 20,000  g for
10 min. The pellet was resuspended in 15% Percoll (Sigma) and layered
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on a preformed Percoll gradient (40 and 23%). After centrifugation at
30,000  g for 6 min, the mitochondrial fraction located at the interface
of the lower two layers was removed, diluted with isolation buffer, and
centrifuged at 16,600  g for 10 min. The supernatant was discarded,
and the loose pellet was resuspended in isolation buffer and centrifuged
at 6700  g for 10 min. The resulting pellet was suspended in 100 l of
isolation medium devoid of EGTA.
Mitochondrial Ca2 Uptake—Mitochondrial-dependent removal of
medium Ca2 was followed using the impermeant pentapotassium salt
of the ratiometric dye Fura 6F (Molecular Probes, Portland, OR, USA).
Fura 6F (250 nM) was added to a medium containing mitochondria (0.25
mg/ml) and 125 mM KCl, 20 mM Hepes, 2 mM KH2PO4, 1 M EGTA, 4
mM MgCl2, 3 mM ATP, 5 mM malate, and 5 mM glutamate with the pH
adjusted to 7.08 with KOH. According to calculations using the Win-
maxc software (34), the free [Mg2] under these conditions is 1 mM. It
was necessary to use Suprapur KCl (Merck) to minimize Ca2 contam-
ination, thereby also minimizing the amount of added EGTA necessary
to eliminate deleterious effects of background Ca2. All experiments
were performed at 37 °C. Fluorescence intensity was measured in a
Hitachi F-2500 fluorescence spectrophotometer (Tokyo, Japan) using
340/380-nm excitation and 510-nm emission wavelengths. The [Ca2] in
the medium was calculated using the ratio calibration approach de-
scribed by Grynkiewicz et al. (35). The Kd for Fura 6F was estimated to
be 2.47 M using the calcium calibration buffer kit number 3 (Molecular
Probes). An essentially identical value was obtained using the calcium
calibration buffer kit number 2 with magnesium (Molecular Probes).
Mitochondrial Membrane Potential—Mitochondrial membrane po-
tential was qualitatively assessed by TMRE (Molecular Probes) fluores-
cence intensity measured in a Hitachi F-2500 fluorescence spectropho-
tometer using 549- and 580-nm wavelengths for excitation and
emission, respectively (37 °C). Because of the small Stokes shift, we
assessed the effect of light scatter on the fluorescent signal, and it was
found to be less than 10% as compared with TMRE fluorescence. 125 nM
dye was added to a medium containing mitochondria (0.25 mg/ml) and
125 mM KCl, 20 mM Hepes, 2 mM KH2PO4, 1 M EGTA, 4 mM MgCl2, 3
mM ATP, 5 mM malate, and 5 mM glutamate with the pH adjusted to
7.08 using KOH.
Oxygen Consumption—Mitochondrial respiration was recorded at
37 °C with a Clark-type oxygen electrode (Hansatech, UK). The incu-
bation medium contained 125 mM KCl, 20 mM Hepes, 2 mM KH2PO4, 1
M EGTA, 1 mMMgCl2, 0.8 mM ADP, 5 mMmalate, and 5 mM glutamate
(or 5 mM succinate plus 1 M rotenone) with the pH adjusted to 7.08
with KOH. In some experiments as indicated 5 mM succinate (plus 1 M
rotenone) replaced malate plus glutamate as the oxidizable substrate.
State 3 (phosphorylating) respiration was initiated by the addition of
mitochondria (0.5 mg/ml) to the incubation medium. State 3 respiration
was terminated and State 4 (resting) respiration was initiated by the
addition of 2 M oligomycin.
Cytochrome c Release from Mitochondria—Aliquots of mitochondrial
suspensions were taken at specified incubation times, and the mito-
chondria were separated from the suspending medium by centrifuga-
tion at 14,000  g for 3 min. The supernatant was carefully removed,
and both the supernatant and mitochondrial pellet fractions were im-
mediately frozen and stored at20 °C. Cytochrome c immunoreactivity
was quantified in both fractions using an enzyme-linked immunosor-
bent assay kit (R&D Systems, Minneapolis, MN). Before measurement,
the supernatant and pellet samples were diluted 1:40 and 1:80, respec-
tively. The release of cytochrome c from mitochondria is expressed as
the content of cytochrome c in the supernatant as a percentage of the
total content of cytochrome c present in the supernatant plus pellet.
NAD  NADH Release from Mitochondria—Aliquots of mitochon-
drial suspensions were taken at specified incubation times, and mito-
chondria were separated from the suspending medium by centrifuga-
tion at 14,000  g for 3 min. The supernatant was carefully removed,
and both the supernatant and mitochondrial pellet fractions were im-
mediately frozen and stored at 20 °C. NAD plus NADH extraction
from both fractions was performed according to the method described by
Klingenberg (36). Extracts were transferred to 2 ml of assay medium
maintained at 30 °C containing 0.2 mg of alcohol dehydrogenase (Sig-
ma), 50 mM Tris-HCl, 0.6 M ethanol, 50 mM Na4P2O710 H2O, pH 7.8.
NADH fluorescence was followed in a Hitachi F-2500 fluorescence spec-
trophotometer using 340- and 460-nm wavelengths for excitation and
emission, respectively.
Mitochondrial Swelling—Swelling of isolated mitochondria was as-
sessed by measuring light scatter at 660 nm (37 °C) in a Hitachi F-2500
fluorescence spectrophotometer. Mitochondria were added at a final
concentration of 0.25 mg/ml to 2 ml of medium containing 125 mM KCl,
20 mM Hepes, 2 mM KH2PO4, 1 M EGTA, 1 mM MgCl2, 5 mM malate,
and 5 mM glutamate with the pH adjusted to 7.08 with KOH. At the end
of each experiment, the non-selective pore-forming peptide alamethicin
(80 g) was added as a calibration standard to cause maximal swelling.
Reagents—Standard laboratory chemicals were from Sigma. 2-APB
(Sigma), CGP 37157 (Calbiochem), cyclosporin A (Sigma), bongkrekic
acid (Calbiochem), alamethicin (Sigma), tamoxifen (Sigma), spermine
(Sigma), xestospongin C (Calbiochem), inositol 1,4,5-triphosphate
(ICN), thapsigargin (Calbiochem), trifluoperazine (Sigma), bromoenol
lactone (Sigma), aristolochic acid (Biomol), bovine serum albumin (Sig-
ma), 7-nitroindazole (Calbiochem), 1400W (Calbiochem), ubiquinone 0
(Sigma), butylated hydroxytoluene (Sigma), N-acetylcysteine (Sigma),
catalase (Sigma), and superoxide dismutase (Sigma).
RESULTS
2-APB Protects against Ca2-induced Mitochondrial Swell-
ing in the Absence of Adenine Nucleotides—Ca2-induced swell-
ing of brain mitochondria can be demonstrated, but typically,
only if adenine nucleotides are omitted from the medium (26).
Under these conditions, non-synaptosomal brain mitochondria
exposed to 20 nmol of Ca2 (40 nmol mg1 protein) (Fig. 1a,
curve a) exhibited a gradual decline in absorbance at 660 nm
greater than that observed in the absence of added Ca2 (Fig.
1a, curve d). The presence of cyclosporin A (2 M) completely
eliminated the Ca2-dependent change in light scattering, in-
dicating involvement of the PTP (Fig. 1a, curve b). 2-APB (100
M) also eliminated the Ca2-dependent light scattering (Fig.
1a, curve c). Because agents that block mitochondrial Ca2
uptake also block mitochondrial swelling without necessarily
affecting the PTP, the effect of 2-APB on mitochondrial Ca2
uptake and release was measured. After the addition of 20
FIG. 1. a, effect of 2-APB versus cyclosporin A versus vehicle (ethanol)
on the calcium-induced mitochondrial swelling in the absence of ade-
nine nucleotides, estimated by light scatter at 660/660 nm. Shown are
2-APB (100 M, curve c) or vehicle (2 l, without the subsequent addi-
tion of calcium (curve d)) with the subsequent addition of calcium (curve
a) or cyclosporin A (2 M, curve b) added at 50 s and 20 nmol of CaCl2
added at 350 s. Alamethicin (ALM), 80 g, was added at 1400 s. The
graph is typical and is one of three independent experiments. b, effect of
2-APB on mitochondrial Ca2 uptake in the absence of adenine nucle-
otides. Thick line, 2-APB (100 M) added at 50 s and 20 nmol CaCl2
added at 450 s. Thin line, 20 nmol of CaCl2 added at 450 s. The graph
is typical and is one of three independent experiments. A.U.,
arbitrary units.
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nmol of Ca2 to the mitochondrial suspension, Ca2 uptake
was faster in the presence of 2-APB than in its absence (Fig. 1b,
thick versus thin line). Thus, in the absence of adenine nucle-
otides, both cyclosporin A and 2-APB are effective inhibitors of
the Ca2-induced PTP in brain mitochondria.
Dose-dependent Inhibition of Mitochondrial Ca2-induced
Ca2 Release by 2-APB in the Presence of ATP—After a dem-
onstration that 2-APB is effective at inhibiting PTP in the
absence of adenine nucleotides, subsequent experiments were
performed in the presence of 3 mM ATP to model more physi-
ologically relevant conditions. In the presence of ATP, brain
mitochondria completely accumulated two additions of 400
nmol of Ca2 and almost sequestered the third addition. This
net uptake of more than 2000 nmol of Ca2mg1 mitochondrial
protein was followed by a slow release of Ca2 back to the
medium (Fig. 2, curve a). Mitochondria suspended in the pres-
ence of either 50 or 100 M 2-APB accumulated the entire Ca2
load (2400 nmol mg1) without releasing Ca2 during the
course of the 20-min experiment (Fig. 2, curves c and d, respec-
tively). The presence of even 10 M 2-APB resulted in some
inhibition of Ca2-induced Ca2 release (Fig. 2, curve b).
Fura 6F fluorescence responds reliably to [Ca2] in the range
of 0.5–50 M (not shown). Each addition of Ca2 to the mito-
chondrial suspension was a total of 200 M; however, according
to Winmaxc software (34), the calculated free [Ca2] was 100
M in the presence of Mg2 and ATP. Therefore, the peak of the
calcium signal before the onset of calcium uptake by mitochon-
dria was underestimated. However, the method used (manual
additions of calcium in a cuvette system) is limited in the
temporal dimension of the millisecond scale, where much of the
calcium uptake takes place, given the enormous avidity of the
uniporter (Vmax  1200 nmol Ca
2/mg of protein/min) and/or
the rapid mode of uptake (37). It is to be noted that even though
the upper range of the bulk [Ca2]i in cells reported by Fura 2
(or higher Kd derivatives) fluorescence is in the relatively low
micromolar range (38), free [Ca2]i may well reach the 100
M range in certain microdomains (39) such as the perimito-
chondrial environment (40), (41).
Comparison of 2-APB to Cyclosporin A and Bongkrekic
Acid—Although cyclosporin A was effective at inhibiting the
PTP in brain mitochondria in the absence of adenine nucleo-
tides (Fig. 1a), it failed to inhibit mCICR in the presence of ATP
(Fig. 3, curve b). Bongkrekic acid, another PTP inhibitor, ex-
hibited an ability to inhibit mCICR in the presence of ATP (Fig.
3, curve c) that was very similar to that of 2-APB (Fig. 3, curve
d). Because the vehicle for bongkrekic acid is 1 M NH4OH, an
equal volume of vehicle was tested and found to have no effect
on Ca2 uptake and retention (not shown). Although 2-APB
inhibited mCICR, it did cause a slight reduction in the rate of
Ca2 uptake, particularly after the third addition of Ca2 (Fig.
3, curve d). The effects of 2-APB on mitochondrial bioenergetics
were further analyzed using measurements of both mitochon-
drial membrane potential and O2 consumption.
Protection by 2-APB against Ca2-induced Loss of Mitochon-
drial Membrane Potential—Fig. 4 provides a qualitative eval-
uation of  after the addition of high Ca2 loads in the
absence and presence of 2-APB (100 M) using the fluorescent
dye TMRE. In the absence of 2-APB, TMRE fluorescence sta-
bilized within 2 min after the addition of mitochondria to the
medium (Fig. 4a). The subsequent addition of 400 nmol of Ca2
caused an immediate increase in fluorescence, i.e. decrease in
, as expected because of the collapse of  during rapid
Ca2 influx. After the 100-s period, during which added Ca2
was accumulated, the TMRE fluorescence decreased but re-
mained much higher than the original fluorescence in the ab-
sence of Ca2. A similar pattern was observed after the second
addition of Ca2. After the third addition, the TMRE fluores-
cence failed to return toward base line and gradually increased
for many minutes thereafter. When 2-APB was added to the
mitochondrial suspension (Fig. 4b), TMRE fluorescence in-
creased, indicating some reduction in  by this compound.
However, unlike what was observed in the absence of 2-APB,
the subsequent addition of three pulses of Ca2 were followed
by a return of TMRE fluorescence toward, and eventually to the
level maintained before these additions. Thus, at 800 s of
incubation,  approached complete depolarization in the ab-
sence of 2-APB but was at least partially retained in its pres-
ence. These observations are consistent with the onset of
mCICR in the absence but not in the presence of 2-APB, also
observed at 800 s of incubation. Although 2-APB by itself
causes partial mitochondrial depolarization, this effect was not
strong enough to impair net -dependent Ca2 uptake. It
must be emphasized that because of the Nernst equation, data
from potentiometric dyes follow a logarithmic, not linear rela-
tionship (42). The observation that is intended for demonstra-
tion on this experiment is that mitochondria depolarize further
upon completion of Ca2 uptake (Fig. 4a) unless they are pre-
treated with 2-APB (Fig. 4b). The onset of depolarization upon
high Ca2 loading (700 s) coincides exactly with the onset of
FIG. 2. Dose-dependent effect of 2-APB on mCICR followed by
Fura 6F fluorescence (calibrated data). 2-APB was added at 50 s,
and 400 nmol of CaCl2 added at 350, 500, and 600 s. a, no 2-APB added;
b, 10 M 2-APB; c, 50 M 2-APB; d, 100 M 2-APB. The graph is typical
and is one of four independent experiments.
FIG. 3. Effect of 2-APB (100 M) and bongkrekic acid (20 M)
versus cyclosporin A (2 M) on mCICR followed by Fura 6F
fluorescence (calibrated data). The additions of the drugs are indi-
cated by the arrows. 2-APB, cyclosporin A, or bongkrekic acid were
added at 50 s; 400 nmol of CaCl2 added at 350, 500, and 600 s. a, no
additions; b, 2 M cyclosporin A; c, 20 M bongkrekic acid; d, 100 M
2-APB. The graph is typical and is one of four independent experiments.
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Ca2 release (Fig. 2, curve a). The choice of the membrane
potential-sensitive probe was critical. Many of the available
probes were tested (safranin O, tetramethylrhodamine meth-
ylester perchlorate (TMRM), rhodamine 123, JC-1), but they all
exhibited serious drawbacks due to the necessity of high cal-
cium loading; i.e. safranin O reduced maximal calcium uptake
capacity considerably, as has also been found by other labora-
tories (43), TMRM and rhodamine 123 were very strong respi-
ratory inhibitors and uncouplers even at low concentrations (20
nM, not shown), affecting respiration more than TMRE al-
though the opposite has been observed for rat heart mitochon-
dria (44), and JC-1 gave an unsatisfactory signal-to-noise ratio
but no suppression of respiratory control (not shown).
Inhibition of Ca2-induced Mitochondrial Cytochrome c and
Pyridine Nucleotide Release by 2-APB—Release of the mito-
chondrial intermembrane protein cytochrome c typically ac-
companies the osmotic swelling and rupture of the outer mem-
brane evoked by activation of the PTP (45–47). Loss of
mitochondrial matrix pyridine nucleotides is another measure
of the PTP, distinguishing it from a mechanism of depolariza-
tion mediated by activation of a “low conductance” pore (48).
Fig. 5 provides the results of enzyme-linked immunosorbent
assay determinations of cytochrome c released into the medium
after the addition of Ca2 and a comparison of the effectiveness
of 2-APB and cyclosporin A at inhibiting this release. In the
absence of added Ca2, less than 10% of total mitochondrial
cytochrome c was lost to the suspending medium after 1800 s of
incubation. After the addition of 2400 nmol of Ca2 mg1
protein, 58% of total cytochrome c was released at 1800 s. No
net release was observed at 700 s, immediately before net Ca2
release was observed (Fig. 3). 2-APB but not cyclosporin A
inhibited Ca2-induced cytochrome c release, consistent with
the differences in the effects of these drugs observed on
mCICR. The same pattern was observed for release of matrix
pyridine nucleotides (Fig. 6). The appearance of pyridine nu-
cleotides in the medium over that observed in the absence of
Ca2 occurred after the onset of mCICR and was inhibited by
2-APB but not cyclosporin A.
Effects of 2-APB on Mitochondrial Bioenergetics and Rela-
tionship to Inhibition of mCICR—The effects of 2-APB on res-
FIG. 6. NAD  NADH release (% of the total) estimated as
described under “Experimental Procedures” from mitochon-
dria incubated in the presence or absence of 2-APB or cyclos-
porin A and challenged by high calcium loading. CaCl2: no
calcium added;CaCl2 700 s:,400 nmol of CaCl2 was added at 350, 500,
and 600 s, and the sample was collected at 700 s; CaCl2 1800 s, 400
nmol of CaCl2 was added at 350, 500, and 600 s, and the sample was
collected at 1800 s; CaCl2  2-APB 1800 s, 100 M 2-APB was added
at 50 s, 400 nmol of CaCl2 was added at 350, 500, and 600 s, and the
sample was collected at 1800 s; CaCl2  Cys A 1800 s, 2 M cyclos-
porin A (Cys A) was added at 50 s, 400 nmol of CaCl2 was added at 350,
500, and 600 s, and the sample was collected at 1800 s. Samples were
sedimented at 14,000  g for 3 min, and both supernatants and pellets
were probed for pyridine nucleotides. *, significant, p  0.05, one-way
analysis of variance, Dunnett’s post hoc analysis, n 	 4.
FIG. 4. a, effect of high calcium loading on  based on TMRE
fluorescence. 400 nmol of CaCl2 added at 350, 500, and 600 s. The graph
is typical and is one of four independent experiments. b, effect of
pretreatment of 2-APB (100 M) and high calcium loading of mitochon-
dria on  based on TMRE fluorescence. 400 nmol of CaCl2 was added
at 350, 500, and 600 s. The graph is typical and is one of four independ-
ent experiments. A.U., arbitrary units.
FIG. 5. Cytochrome c release (% of the total) estimated by
enzyme-linked immunosorbent assay from mitochondria incu-
bated in the presence or absence of 2-APB or cyclosporin A and
challenged by high calcium loading. CaCl2, no calcium added;
CaCl2 700 s, 400 nmol of CaCl2 was added at 350, 500, and 600 s, and
the sample was collected at 700 s; CaCl2 1800 s, 400 nmol of CaCl2
was added at 350, 500, and 600 s, and the sample was collected at
1800 s; CaCl2  2-APB 1800 s, 100 M 2-APB was added at 50 s, 400
nmol of CaCl2 was added at 350, 500, and 600 s, and the sample was
collected at 1800 s; CaCl2  Cys A 1800 s, 2 M cyclosporin A (Cys A)
was added at 50 s, 400 nmol of CaCl2 was added at 350, 500, and 600 s,
and the sample was collected at 1800 s. Samples were sedimented at
14,000 g for 3 min, and both supernatants and pellets were probed for
cytochrome c, *, significant, p  0.05, one-way analysis of variance,
Dunnett’s post hoc analysis, n 	 4.
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piration by isolated non-synaptosomal brain mitochondria are
described in Table I. 2-APB exhibited a dose-dependent inhibi-
tion of State 3 respiration with the NADH-linked oxidizable
substrates malate plus glutamate, with significant inhibition
observed at a concentration of 10 M and a 57% inhibition
observed at 100 M. 2-APB similarly inhibited uncoupler
(FCCP) stimulated respiration (not shown). State 4 respiration
was significantly elevated at 10 M 2-APB and was approxi-
mately twice the control rate at 100 M. Qualitatively similar
results were obtained with mitochondria respiring on succinate
in the presence of rotenone (Table I). These results indicate
that 2-APB is both a mild respiratory inhibitor and uncoupler
at concentrations that protect against activation of the PTP.
The possibility that 2-APB protection against mCICR is re-
lated to its effects on respiration was tested by measuring
mitochondrial Ca2 uptake and release in the presence of tar-
geted respiratory inhibition. When NADH-linked respiration is
completely inhibited by rotenone, active Ca2 uptake can still
be driven by  established via ATP-dependent H export
catalyzed by the mitochondrial F0 F1-ATPase (49). As shown
in Fig. 7a, the onset of mCICR in the presence of rotenone
occurred at a smaller Ca2 load (800 nmol) than that required
in the absence of rotenone (1200 nmol; Fig. 2). Under this state
of complete respiratory inhibition, 100 M 2-APB still inhibited
mCICR (Fig. 7a, thick versus thin line), indicating that its
moderate inhibition of O2 consumption is unrelated to its abil-
ity to inhibit the PTP. Ca2 uptake was slower in the presence
of 2-APB, likely due to its moderate uncoupling effect.
The possible dependence of 2-APB protection against mCICR
on mitochondrial ATP hydrolysis was tested by exposing mito-
chondria to Ca2 in the absence of rotenone but in the presence
of the ATPase inhibitor oligomycin. Under this condition,
mCICR was also activated by 800 nmol of Ca2 and inhibited
by 2-APB (Fig. 7b). Ca2 influx was significantly slower in the
presence of 2-APB, as expected by the inhibition of ATPase-de-
pendent Ca2 uptake (50) together with the inhibition of res-
piration by 100 M 2-APB. The observations that 2-APB is
effective at inhibiting mCICR in the absence and the presence
of either rotenone or oligomycin indicates that its mechanism is
closely related to pore opening and not due to its moderate
effects on mitochondrial bioenergetics. In addition to that, mod-
erate uncoupling could prove beneficial to a mitochondrion
against noxious stimuli, lowering its ability to form free radi-
cals at a basal level (51). Therefore, FCCP concentration was
titrated to confer the same extent of depolarization (30 nM, Fig.
7c, curve a) and activation of state 4 respiration (5 nM, Fig. 7c,
curve b), and this range of concentration was tested as a pos-
sible protectant against PTP; under these conditions, mCICR
was still present.
Inhibition of Mitochondrial Na/Ca2 Exchanger Does Not
Reproduce the Effect of 2-APB—Studies demonstrating 2-APB
inhibition of mitochondrial Ca2 efflux after a capacitative
Ca2 entry event hypothesized the involvement of the mito-
chondrial Na/Ca2 exchanger (32). Pretreatment of isolated
brain mitochondria with the inhibitor of the Na/Ca2 ex-
changer CGP 37157 (20 M) in the absence of Na did not
inhibit mCICR and actually promoted the release of Ca2 (Fig.
8, curve a). Moreover, the simultaneous presence of 2-APB (100
M) and CGP 37157 (20 M) resulted in much slower Ca2
uptake and partial antagonism of the protective effect of 2-APB
(Fig. 8, curve c; compare with Fig. 3, curve d). When medium
K was substituted for Na at 10–40 mM, mCICR was unaf-
fected and was not inhibited by CGP 37157 (not shown). It
therefore appears that Na/Ca2 exchange activity does not
contribute to the mCICR observed in these experiments and is
not a target of 2-APB.
Comparison of 2-APB with Other PTP Inhibitors—Experi-
ments identical to that described by Fig. 2 performed in the
presence of NADH-linked substrates and ATP were conducted
in the presence of other compounds reported to inhibit the PTP
or other related cellular activities. Results are expressed as the
concentration of medium-free Ca2 present at 1800 s of mito-
chondrial incubation and after three additions of 400 nmol of
Ca2. Although the presence of 100 M 2-APB allowed brain
mitochondria to maintain the medium [Ca2] at 1 M, no
compound other than bongkrekic acid inhibited mCICR to an
extent that allowed for maintenance of the medium [Ca2] at
20 M. These compounds included phospholipase A2 inhibi-
tors, i.e. trifluoperazine, bromoenol lactone, and aristolochic
acid (52), (53, 54), BSA, which binds free fatty acids, antioxi-
dants, i.e. superoxide dismutase, catalase, N-acetylcysteine,
butylated hydroxytoluene, ubiquinone 0 (55), inhibitors of ni-
tric-oxide synthesis, i.e. 7-nitroindazole and 1400 W (56), and
other agents, e.g. spermine and tamoxifen (57, 58), which in-
hibit the PTP by other mechanisms. Xestospongin C, a potent
inositol 1,4,5-triphosphate receptor blocker (59), was also
tested due to the fact that it has been proposed to resemble the
active, dimerized form of 2-APB (Ref. 60, but see also Dobryd-
neva and Blackmore (61)). Because of the documented inhibi-
tory effect of 2-APB on inositol 1,4,5-triphosphate receptors
(30) and sarco-endoplasmic reticulum Ca2 ATPase pump (62),
it was prudent to exclude the conception that the increase of
Ca2 in the medium and its inhibition by 2-APB upon high
calcium loading was attributed to contaminating microsomes
and/or endoplasmic reticulum. The addition of inositol 1,4,5-
triphosphate (100 M) or thapsigargin (2 M) upon completion
of Ca2 uptake did not cause any acceleration of Ca2 release
(not shown).
DISCUSSION
The most important new information obtained from these
experiments is the identification of 2-APB as an agent capable
of inhibiting the PTP in brain mitochondria under physiologi-
cally relevant in vitro conditions in the presence of millimolar
concentrations of ATP. The ability to block PTP in the presence
of adenine nucleotides is also relevant to the potential involve-
ment of PTP in ischemic brain injury. Even though ATP levels
may fall to less than the millimolar range during ischemic
deenergizing, ADP levels approximate 400 M (63), and the Ki
for inhibition of the PTP by ADP is in the low micromolar range
(64). Although both 2-APB and the classical PTP inhibitor
cyclosporin A inhibit the PTP in the absence of adenine nucle-
otides (Fig. 1), neither cyclosporin A or a host of other agents
that are reported to inhibit mitochondrial permeability transi-
TABLE I
Dose-dependent effect of 2-APB on oxygen consumption (nmol O2/min/mgol protein), driven by NAD-linked (glutamate  malate) or FADH2-
linked (succinate) substrates. NS, not significant.
Substrate
Glutamate (5 mM)  malate (5 mM) Succinate (5 mM)  rotenone (1 M)
Control 1 M 2-APB 10 M 2-APB 50 M 2-APB 100 M 2-APB Control 100 M 2-APB
State 3 137 
 14 137 
 13 (NS) 96 
 2a 79 
 10a 67 
 3a 141 
 3 96 
 2b
State 4 15 
 1 16 
 2 (NS) 25 
 1a 27 
 1a 31 
 2a 35 
 2 51 
 1b
a significant, p  0.05 one-way analysis of variance, Dunnett’s post hoc analysis.
b significant, p  0.001, Student’s t test, (n 	 4).
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tion under some conditions is capable of inhibiting the PTP in
non-synaptosomal brain mitochondria in the presence of ATP
(Fig. 2 and Table II). Inhibition of PTP by cyclosporin A is
variable (27, 65), pointing to the possibility of the presence of a
more fundamental constituent of PTP other than the one con-
ferring its cyclosporin A sensitivity. Such a constituent is exem-
plified by the effect of bongkrekic acid. Other than 2-APB, this
compound is the only reported PTP inhibitor to block mCICR in
brain mitochondria in the presence of ATP (Fig. 3 and Table II).
Bongkrekic acid locks the adenine nucleotide translocator at the
M configuration. This protein has been implicated as a compo-
nent of a multiprotein complex that constitutes the PTP (8).
Bongkrekic acid, at concentrations required to inhibit the PTP,
completely inhibits State 3 respiration due to the inhibition of the
adenine nucleotide translocator. 2-APB also inhibits respiration
but to a much smaller extent (Table I). Because both ADP- and
FCCP-stimulated respiration are affected by 2-APB, it likely
affects the electron transport chain rather than adenine nucleo-
tide transport.
Experiments were performed to determine whether the ef-
fects of 2-APB on respiration and  are related to its PTP
inhibitory activity. 2-APB inhibited mCICR in the presence of
the respiratory inhibitor rotenone and in the presence of the
ATP synthase inhibitor oligomycin (Fig. 7, a and b, respective-
FIG. 7. a, effect of 2-APB on mCICR in the presence of rotenone (1 M)
followed by Fura 6F fluorescence (calibrated data). 2-APB (100 M) was
added at 50 s, rotenone (Rot.) was added at 100 s, and 400 nmol of CaCl2
was added at 350 and 550 s; thick line, mitochondria treated with
2-APB. The graph is typical and is one of three independent experi-
ments. b, effect of 2-APB on mCICR in the presence of oligomycin (2 M)
followed by Fura 6F fluorescence (calibrated data). 2-APB (100 M) was
added at 50 s, oligomycin was added at 100 s, and 400 nmol of CaCl2
added at 350 and 550 s; thick line, mitochondria treated with 2-APB.
The graph is typical and is one of three independent experiments. c,
effect of moderate uncoupling by FCCP on mCICR followed by Fura 6F
fluorescence (calibrated data). FCCP added at 50 s, and 400 nmol of
CaCl2 was added at 350, 500, and 600 s. Curve a, 30 nM FCCP; curve b,
5 nM FCCP. The graph is typical and is one of three independent
experiments.
FIG. 8. Effect of CGP 37157 in the presence and absence of
2-APB on mCICR followed by Fura 6F fluorescence (calibrated
data). a, CGP 37157 (20 M) was added at 50 s, and 400 nmol of CaCl2
was added at 350, 500, and 600 s. b, 400 nmol of CaCl2 was added at
350, 500, and 600 s. c, CGP 37157 (20 M) was added at 50 s, 2-APB was
added at 100 s, and 400 nmol of CaCl2 was added at 350, 500, and 600 s.
The graph is a typical and is one of three independent experiments.
TABLE II
2-APB effect upon high calcium loading of brain mitochondria and
subsequent Ca2 release versus previously identified PTP inhibitors.
Mitochondria were pretreated with each compound at 50 s, then 400
nmol of CaCl2 was added at 350, 500, and 600 s
Inhibitor [Ca2] at 1800 s
M
No additions 21.2 
 2.8
2-APB (100 M) 0.64 
 0.12a
Cyclosporin A (1 M) 18.2 
 0.24
Bongkrekic acid (20 M) 0.62 
 0.14a
Trifluoperazine (100 M) 20.2 
 2.4
Bromoenol lactone (10 M) 21.1 
 2.8
Aristolochic acid (50 M) 20.8 
 2.0
Bovine serum albumin (fatty acid-free) (0.1 %) 22.2 
 2.4
Spermine (100 M) 20.3 
 2.2
7-Nitroindazole (100 M) 22.6 
 2.5
1400W (100 M) 21.9 
 2.9
Ubiquinone 0 (10 M) 20.2 
 2.7
Butylated hydroxytoluene (100 M) 19.5 
 2.5
N-Acetylcysteine (5 mM) 22.2 
 2.1
Catalase (100 units) 21.1 
 2.3
Superoxide dismutase (40 units) 21.2 
 2.7
Tamoxifen (0.3–10 M) 20.1 
 2.1
Xestospongin C (1 M) 22.3 
 2.3
a Significant, p  0.05 one-way analysis of variance, Dunnett’s post
hoc analysis, n 	 3.
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ly). Moreover, mCICR was not inhibited by the protonophore
FCCP at a concentration that mimics the respiratory uncou-
pling and mitochondrial membrane depolarization observed
with 100 M 2-APB (Fig. 7c). Therefore, the moderate effects of
2-APB on respiration are unrelated to its potent inhibition of
the PTP. Although moderate respiratory inhibition by 2-APB is
not responsible for PTP inhibition, it probably accounts for the
slightly slower rate of Ca2 uptake observed in the presence of
2-APB in the presence of ATP (Figs. 2 and 3). In the absence of
ATP, however, 2-APB actually accelerated the rate of mito-
chondrial net Ca2 uptake (Fig. 1b). In the absence of ATP,
even small additions of Ca2 induce the PTP in a significant
fraction of the mitochondrial population (26), thereby reducing
the number of mitochondria capable of energy-dependent Ca2
accumulation. Thus, 2-APB accelerates Ca2 uptake in the
absence of ATP by maintaining a larger population of energized
mitochondria.
The PTP can assume different conductance states, including
that of a low conductance pore (4), that causes membrane
depolarization but not osmotic lysis unless followed by transi-
tion to a high conductance permeability (66). Because the
mCICR observed in our experiments was accompanied by re-
lease of cytochrome c and pyridine nucleotides at 800 s of
incubation (Figs. 5 and 6, respectively), the high conductance
pore was clearly activated at this time. The additional obser-
vation that  was reduced by Ca2 additions before release of
pyridine nucleotides and cytochrome c supports the possibility
that activation of the low conductance pore preceded that of
the high conductance PTP (Fig. 4a). It is therefore possible
that 2-APB inhibits the transition from the low to high con-
ductance mode (66). The addition of ruthenium red (1 M) or
its purified active component Ru360 (165 nM) just before the
onset of mCICR induced an abrupt release of Ca2, support-
ing the possibility of an induction of Ca2 cycling across the
mitochondrial membrane (18, 67), leading progressively to open-
ing of the pore throughout the heterogeneous mitochondrial
population (26).
Inhibition of the consequences of PTP activation on brain
mitochondria by 2-APB provides a rationale for testing the
potential neuroprotective actions of this compound. Despite the
mild uncoupling effect of 2-APB, it protected against complete
depolarization caused by mitochondrial Ca2 overload (Fig. 4b)
and, therefore, protects against Ca2-induced impairment of
oxidative phosphorylation. 2-APB also prevented the loss of
matrix pyridine nucleotides and cytochrome c, both also neces-
sary for respiration and oxidative phosphorylation. Release of
cytochrome c can stimulate mitochondrial production reactive
oxygen species (68), and loss of pyridine nucleotides and other
matrix compounds, e.g. glutathione, can compromise their de-
toxification. Thus, 2-APB may protect against Ca2-induced
mitochondrial oxidative stress as well as metabolic failure.
The results of this investigation also relate to the contribu-
tion of mitochondrial Ca2 transport to normal cellular Ca2
homeostasis and signal transduction. Mitochondria within cells
may form an electrically coupled network, synchronizing elec-
trical signals generated by the PTP (69). Ca2 plays a pivotal
role in induction and priming of the PTP. Therefore, PTP
inhibitors and other agents that modulate mitochondrial Ca2
handling can be useful tools to elucidate the roles of mitochon-
dria in Ca2-mediated signal transduction.
In addition to our demonstration that 2-APB is an effective
blocker of PTP, this compound is a blocker of store-operated
Ca2 entry (70), a phenomenon recently identified to be cen-
trally positioned among signal transduction and [Ca2]i home-
ostasis in both excitable and non-excitable cells (71). Inhibition
of SOCE by 2-APB was attributed to impairment of both ino-
sitol 1,4,5-triphosphate-mediated Ca2 release (30) and inhibi-
tion of TRP channels (72), (73). However, TRP channels have
yet to be unequivocally established as the molecular basis for
SOCE (74). 2-APB also inhibits the sarco-endoplasmic reticu-
lum Ca2 ATPase pump (62) and voltage-dependent K chan-
nels (75) and blocks gap junctions, possibly by interfering with
the docking interactions of two gap junctional hemi-channels
(76).
Activation of the mitochondrial PTP may oppose SOCE,
based on the fact that SOCE is inhibited by high [Ca2]i and
the observation that abolition of Ca2 uptake by mitochondria
inactivates SOCE (77–79). Thus, it is possible that release of
mitochondrial Ca2 stores through activation of the PTP ele-
vate [Ca2]i, thereby inhibiting SOCE. Interpretation of results
obtained from SOCE measurements in the presence of 2-APB
is, therefore, potentially complicated by the effect this agent
has on mitochondrial Ca2 handling.
Considering the reported effects of 2-APB on TRP channels,
we attempted to identify immunoreactivity of TRP family mem-
bers (TRPC1, -3, -4, -6) in highly purified mitochondrial sub-
fractions (outer membrane, contact sites, inner membrane) but
were unsuccessful (not shown). 2-APB may block the activation
machinery of the channels participating in SOCE and not the
channels themselves (80), (81). Therefore, 2-APB-sensitive
channel-activating proteins similar to those involved in SOCE
may be present in mitochondria in the absence of TRP chan-
nels. These proteins may interact with one or more of the many
mitochondrial cation channels that have been identified elec-
trophysiologically but not adequately characterized (82).
In conclusion, we show that 2-APB inhibits mCICR in iso-
lated non-synaptosomal brain mitochondria in the presence of
adenine nucleotides and magnesium. Neither inhibition of the
reversal of the uniporter nor blockade of the mitochondrial
Na/Ca2 exchanger could reproduce the effect of 2-APB. Ca2
release was accompanied by cyclosporin A-insensitive loss of
cytochrome c and pyridine nucleotide release, signifying acti-
vation of the “high conductance” pore. These observations
taken together with others demonstrating inhibition of SOCE
by 2-APB indicate a mitochondrial site of action for this drug in
addition to other cell membranes.
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